AnGes MG (Japan) announces collaboration with VIDO-InterVac to use DNA vaccination to develop Ebola polyclonal antibody for clinical use.
VIDO's containment level 3 facility, InterVac, is open to collaborators from government, industry and academia. This unique facility provides the technology and capacity to study a wide range of diseases and to develop and test new vaccines.
VIDO-InterVac’s contract research group offers research and evaluation services to the human and animal health biopharmaceutical industries.
VIDO-InterVac is a world leader in infectious disease research and vaccine development. With 150 interdisciplinary personnel, over $200 million in infrastructure and four decades of experience, our team seeks solutions to prevent and control human and animal infectious disease threats.